Personalized Addiction Treatment eHancement

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorRhode Island Hospital

About this trial

Many patients stop medication-based treatments for Opioid Use Disorder (OUD) prematurely, placing them at increased risk for overdose and death. Providing targeted interventions for OUD, particularly through an accessible, digital health platform, is a potential way to enhance recovery and keep patients engaged in care. The current study seeks to test whether a digital mental health platform, delivered by peer recovery support specialists to individuals prescribed buprenorphine or methadone medication, will improve treatment outcomes for this high risk population.

Eligibility criteria

Qualifiers

Age 22+

Current Opioid Use Disorder diagnosis

Prescribed buprenorphine or methadone

Initiated or reinitiated buprenorphine or methadone treatment recently

Disqualifiers

Not fluent in English

Limited mental capacity or inability to provided informed consent

Trial design

Treatments tested in this trial

  • Vira Platform
  • Treatment-As-Usual

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Rhode Island Hospital

Lead sponsor

Ksana Health

Collaborator